more

Envista (NVST)

(Delayed Data from NYSE)

$16.18 USD

-0.32 (-1.94%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $16.18 0.00 (0.00%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5 5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

Top 36% (90 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

by Zacks Equity Research Published on July 13,2021

Investors are optimistic about Hill-Rom (HRC) on robust international growth and raised 2021 outlook.

medical

Medtronic (MDT) Reports Economic Findings on PRODIGY Data

by Zacks Equity Research Published on July 13,2021

Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.

medical

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research Published on July 13,2021

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.

medical

7 Low Price-to-Book Stocks Worth Buying in July

by Kinjel Shah Published on July 12,2021

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

Thermo Fisher's (TMO) Rapid DNA Solution Gets FBI Approval

by Zacks Equity Research Published on July 12,2021

Thermo Fisher's (TMO) RapidHIT ID DNA Booking System allows seamless integration of Rapid DNA into the law enforcement booking agency process.

medical

Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio

by Zacks Equity Research Published on July 12,2021

Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.

medical

Smith+Nephew's (SNN) New Device to Boost Patient Outcomes

by Zacks Equity Research Published on July 12,2021

Smith+Nephew's (SNN) FAST-FLIX FLEX Meniscal Repair System to provide long-term benefits to patients.

medical

Here's Why You Should Retain Merit Medical (MMSI) Stock Now

by Zacks Equity Research Published on July 12,2021

Merit Medical (MMSI) continues to gain traction from robust Peripheral Intervention arm and solid international presence. Forex, although, remains a concern.

medical

Walgreens (WBA), VillageMD State 2021 Primary Healthcare Goal

by Zacks Equity Research Published on July 09,2021

With this Walgreens (WBA) and VillageMD are on track to achieve their January 2021 goal of opening at least 600 Village Medical primary care practices in more than 30 U.S. markets over the next four years.

medical

QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark

by Zacks Equity Research Published on July 09,2021

QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.

medical

Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice

by Zacks Equity Research Published on July 08,2021

Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.

medical

Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics

by Zacks Equity Research Published on July 08,2021

Thermo Fisher's (TMO) new research collaboration is aimed to provide the metabolomics community with advanced, best practices and standard operating procedures.

medical

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research Published on July 08,2021

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.

medical

Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden

by Zacks Equity Research Published on July 07,2021

Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.

medical

IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?

by Zacks Equity Research Published on July 07,2021

Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).

medical

Here's Why You Should Add STERIS (STE) to Your Portfolio

by Zacks Equity Research Published on July 07,2021

Investors are optimistic about STERIS (STE) owing to strong segmental performance and bullish 2022 outlook.

QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt

by Zacks Equity Research Published on July 07,2021

With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.